Ask about this productRelated genes to: EPOr Blocking Peptide
- Gene:
- EPOR NIH gene
- Name:
- erythropoietin receptor
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-05-14
- Date modifiied:
- 2017-07-12
Related products to: EPOr Blocking Peptide
Related articles to: EPOr Blocking Peptide
- Metastatic melanoma is an aggressive, heterogeneous cancer with early spread and poor prognosis. Transcriptomic analysis identifies potential therapeutic targets. In silico analysis of the GEO dataset GSE7553 compared primary vs metastatic melanoma using differential expression, enrichment (GO/KEGG/Reactome), PPI network construction, and hub-gene prioritization. Candidates were validated through survival analysis, mutation-associated analyses, and virtual screening using molecular docking with FDA-approved compounds. Transcriptomic results show divergence between primary and metastatic melanoma samples, with principal component analysis supporting clear group separation. In a total of 54,675 probe-level entries, 4868 were classified as upregulated and 10,269 as downregulated, indicating a predominance of downregulated transcriptional events in metastatic melanoma. Prioritized upregulated genes included CUL5, ZC3H14, SON, BRCC3, and H3-3B, whereas notable downregulated genes included ZNF709, CD84, STARD8, EPOR, and HAVCR2. The high-confidence PPI network comprised 625 nodes and 2661 edges, with a significant enrichment score. Enrichment analysis implicated immune/adhesion and translation pathways (e.g., Rap1, focal adhesion, T-cell activation). Survival: CUL5 (HR = 0.26) and ZC3H14 (HR = 0.60) are protective, while SON (HR = 2.4) is adverse. Mutation-linked transcriptomic analysis identified 10 significantly altered genes, including downregulated SNHG18 and upregulated LPCAT2. Virtual screening results show repurposable compounds, with Floxacrine showing strong predicted affinity for CUL5 and Dihydroergocristine showing favorable interaction with LPCAT2/ZC3H14-related targets. In silico docking results further supported CUL5-Floxacrine and LPCAT2-Dihydroergocristine as notable candidate interactions. Results show key transcriptomic drivers and targets (CUL5, ZC3H14, SON, BRCC3, LPCAT2) in metastatic melanoma. Results highlight a useful hypothesis-generating framework for biomarker prioritization and drug repurposing in melanoma. However, independent cohort validation and experimental confirmation are required before clinical translation. - Source: PubMed
Publication date: 2026/05/02
Majeed Khulood AyadMajeed Raghad AyadIbrahim Taisir KhalilKhan Najeeb Ullah - Elevated erythropoietin (EPO) concentration associates with thrombotic risk in hypoxic conditions, hereditary erythrocytosis and treatment of anaemia with recombinant EPO. We evaluated sickle cell disease (SCD) patients from the University of Illinois at Chicago (UIC) and the Treatment of Pulmonary Hypertension and SCD with Sildenafil Therapy (Walk-PHaSST) study and found that higher serum EPO concentration associated with increased thromboembolic risk (combined odds ratio [OR] = 1.9, p = 0.0029, N = 557). Percent haemoglobin F and haemoglobin concentration strongly correlated with EPO concentration in SCD, and the haemoglobin F locus BCL11A affected EPO concentration through percent haemoglobin F. In peripheral blood mononuclear cells from 159 UIC patients, we identified an expression quantitative trait locus for EPOR encoding EPO receptor, in which the G allele of rs322139 associated with higher EPOR expression (β = 0.055, p = 2.0 × 10). This G allele associated with lower EPO concentration in Walk-PHaSST (β = -0.23, p = 6.4 × 10, N = 327) and UIC (β = -0.18, p = 0.017, N = 179), but not in normal populations. The G allele of rs322139 also associated with a trend to decreased thromboembolism (combined OR = 0.64, p = 0.054, N = 665). In summary, our study indicates that higher serum EPO concentration associates with thromboembolic risk in SCD and reveals a novel role of EPOR expression variation in modulating EPO concentration and, possibly, thromboembolic risk in this condition. - Source: PubMed
Publication date: 2026/04/29
Zhang XuShah Binal NHan JinNouraie MehdiZhang YingzeMachado Roberto FGladwin Mark TSaraf Santosh LGordeuk Victor R - Although stimulation of erythropoietin receptor (EPOR) signaling demonstrates cytoprotective effects-including anti-apoptosis, pro-proliferation, and promotion of inflammation resolution-in various disease models, its alterations and specific role in the process of pulmonary fibrosis are still not well understood. The study aimed at investigating the changes of lung EPOR signal in pulmonary fibrosis and the effect of different cell EPOR signal on pulmonary fibrosis. - Source: PubMed
Wu PengfeiJia JialinJin TianrongLuo BangweiZhang ZhirenWang Guansong - Erythroferrone (ERFE), secreted by erythroblasts, is regarded as a classical regulator of iron metabolism through its suppression of hepcidin. Thus, as a consequence of insufficient hepcidin suppression and reduced iron availability, global mice exhibit delayed recovery after phlebotomy. We have shown previously that, apart from erythroblasts, ERFE is notably expressed in osteoblasts. To explore the effect specifically of osteoblast-derived ERFE during stress erythropoiesis, we first created mice, which were then crossed with -Cre mice to generate osteoblast-selective mutants (or -Cre; mice). The induction of stress erythropoiesis in these latter mice by phlebotomy resulted in reduced serum ERFE levels and increased liver (hepcidin) expression. Importantly, -Cre; mice showed a more robust red blood cell (RBC) recovery 6 d postphlebotomy, with no differences in bone marrow relative to mice. Furthermore, despite no differences in the baseline RBC count, reticulocyte count, spleen size, or bone marrow cellularity, osteoblast-selective ERFE loss resulted in enhanced erythropoietin receptor () and bone morphogenetic protein 4 () expression in whole bone in vivo and in osteoblasts ex vivo. Finally, the osteoblast-selective mutants showed erythroid lineage proliferation and enhanced EPO responsiveness in a BMP4-dependent manner. Taken together, we posit that ERFE loss specifically from osteoblasts enhances RBC recovery during stress erythropoiesis-defining mechanisms of regulation in the crosstalk between osteoblasts and erythroblasts. - Source: PubMed
Publication date: 2026/04/28
Na-Phatthalung PinanongCaloen Gabrielle vanPlanoutene MarinaTai EmilyGumerova AnisaWitztum RonitIngber EvaKautz LeonSultana FarhathKorkmaz FundaLevy MaayanYuen TonyZaidi MoneGinzburg Yelena Z - This study aimed to investigate erythropoietin receptor (EPOR) expression in human AKI and to examine its association with histopathological severity and clinical parameters. - Source: PubMed
Publication date: 2026/04/07
Xie KunZhou GangLi MengjinFu LiliWang RongZhang LimingMei ChanglinXue ChengXu Daoliang